NORGESIC
LOE ApproachingNDAORALTABLET
Approved
Mar 1964
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
NORGESIC by Bausch + Lomb is clinical pharmacology orphenadrine citrate is a centrally acting (brain stem) compound which in animals selectively blocks facilitatory functions of the reticular formation. First approved in 1964.
Drug data last refreshed 9h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NORGESIC is an oral tablet containing orphenadrine citrate combined with aspirin and caffeine, approved in 1964 for muscle pain and spasm. It is a centrally acting agent that blocks facilitatory functions in the brain stem reticular formation, with analgesic and anti-cholinergic properties. The exact mechanism of therapeutic action remains unclear but is thought to relate to its analgesic effects.
LOE Approaching
Product is in late-stage lifecycle with approaching loss of exclusivity; team size and hiring likely constrained.
Mechanism of Action
CLINICAL PHARMACOLOGY Orphenadrine citrate is a centrally acting (brain stem) compound which in animals selectively blocks facilitatory functions of the reticular formation. Orphenadrine does not produce myoneural block, nor does it affect crossed extensor reflexes. Orphenadrine prevents…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on NORGESIC offers limited growth trajectory but provides stability and deep product mastery in a legacy brand. This role suits professionals focused on lifecycle management, generic defense strategies, or organizational efficiency rather than launch or expansion careers.
Worked on NORGESIC at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.